证券代码：300354 证券简称：东华测试 公告编号：2025-028 江苏东华测试技术股份有限公司 第六届董事会第六次会议决议公告 经审议，董事会同意聘任李玲女士为公司财务总监，任期与本届董事会任期 相同。李玲女士的任职资格、岗位胜任能力等相关情况已经公司董事会提名委员 会审查通过，聘任财务总监的事项已经董事会审计委员会审议同意。 审议结果：赞成7票；反对0票；弃权0票，通过。 三、备查文件 1.经与会董事签字的第六届董事会第六次会议决议； 2.第六届董事会提名委员会会议决议； 3.第六届董事会审计委员会会议决议。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东华测试技术股份有限公司（以下简称"公司"）于2025年5月16日在 公司会议室以现场与通讯相结合方式召开了第六届董事会第六次会议，会议通知 及相关资料于2025年5月12日通过邮件方式发出。本次董事会会议应出席董事7 名，实际出席董事7名。会议由董事长刘士钢主持，公司高级管理人员列席了会 议。会议的召集及召开程序符合《中华人民共和国公司法》及《公司章程》的规 定。 二、 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Views - The company reported a significant increase in performance for 2024, with revenue reaching 502 million, a year-on-year increase of 32.79%, and a net profit attributable to shareholders of 122 million, up 38.90% [6][12]. - The company continues to see stable growth in revenue and performance in Q1 2025, with revenue of 109 million, a year-on-year increase of 4.25%, and a net profit of 29 million, up 5.64% [6][12]. - The gross profit margin has improved consistently, with a gross margin of 66.37% in 2024, an increase of 0.9 percentage points year-on-year, and further rising to 68.66% in Q1 2025 [12][12]. - The company is focusing on domestic substitution of mechanical products and aims to build a platform for high-end scientific research instruments, which is expected to open up growth opportunities [12][12]. Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 502 million, with a gross profit of 333 million, resulting in a gross margin of 66% [16]. - The net profit for 2024 was 121 million, with an EPS of 0.88 [16]. - For Q1 2025, the company reported revenue of 109 million and a net profit of 29 million, indicating a stable growth trajectory [6][12]. Business Development - The company has seen growth across multiple product lines, including structural mechanics testing systems and electrochemical workstations, with sales revenue increases of 35.79% and 52.26% respectively [12][12]. - The company is enhancing its R&D efforts, with a 49.40% increase in R&D investment in 2024, amounting to 61.37 million, which represents 12.22% of total revenue [12][12]. Market Position - The company has a strong competitive position in the domestic market for high-end scientific research instruments, with plans to expand product categories and applications [12][12]. - The company is expected to achieve net profits of 170 million and 230 million in 2025 and 2026 respectively, with corresponding P/E ratios of 34x and 25x [12][12].

Core Viewpoint - The company is in the small-batch trial production stage of its six-dimensional force sensor, which has applications in various fields including industrial robots, humanoid robots, automotive, electronics, medical, and aerospace [1][3]. Business Segments and Financial Performance - The company has four main business segments and is expanding into new areas: 1. Structural Mechanics Performance Research: Revenue of 190 million yuan in H1 2024, accounting for 68.87% of total revenue, with a gross margin of 66.32%. This segment is essential for strength testing, fatigue testing, and dynamic characteristic analysis in aerospace, vehicles, civil engineering, and energy sectors [2]. 2. Structural Safety Online Monitoring and PHM: Revenue of 40 million yuan in H1 2024, accounting for 14.51% of total revenue, with a gross margin of 65.45%. This segment focuses on fault prediction and health management using AI and digital twin technologies [2]. 3. PHM-based Intelligent Maintenance Management Platform: Revenue of 14 million yuan in H1 2024, accounting for 5.07% of total revenue, with a gross margin of 63.36%. This platform provides technical support for intelligent maintenance management [2]. 4. Electrochemical Workstation: Revenue of 26 million yuan in H1 2024, accounting for 9.35% of total revenue, with a gross margin of 64.90%. This product is used in various electrochemical research applications [2]. 5. New Business - Custom Measurement and Control Analysis System: Comprises sensors, control systems, and software platforms, providing a complete testing system [2]. Growth Forecast - The company is expected to achieve revenues of 533 million yuan, 691 million yuan, and 864 million yuan from 2024 to 2026, representing year-on-year growth rates of 40.99%, 29.58%, and 25.08% respectively. The net profit attributable to shareholders is projected to be 147 million yuan, 203 million yuan, and 274 million yuan for the same period, with growth rates of 67.15%, 38.15%, and 35.27% respectively [4].

证券代码：300354 证券简称：东华测试 公告编号：2025-027 江苏东华测试技术股份有限公司 2024年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会召开期间无增加、变更、否决提案的情况。 2、本次股东会不涉及变更以往股东会已通过的决议。 3、本次股东会采取现场投票、网络投票相结合的方式召开。 4、为尊重中小投资者利益，提高中小投资者对公司股东会决议事项的参与 度，本次股东会对中小投资者进行单独计票，中小投资者是指除上市公司董事、 监事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外的其他股 东。 一、会议召开和出席情况 1 《关于公司未来三年股东分红回报规划(2025年-2027年)的议案》等九项议案作 为临时提案提交至公司2024年度股东会审议。对此，公司于2025年4月24日披露 了《关于2024年年度股东会增加临时提案暨股东会补充通知的公告》（公告编号： 2025-026）。 （一）会议召开情况 1、会议召开时间 （1）现场会议召开时间为2025年5月9日（星期五）14：00。 （2） ...

北京市东城区 北三环东路 36 号环球贸易中 心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 关 于 江 苏 东 华 测 试 技 术 股 份 有 限 公 司 2024 年 年 度 股 东 会 之 法 律 意 见 书 北 京 市 君 致 律 师 事 务 所 北京市东城区北三环东路 36 号环球贸易中心 B 座 11 层 邮编(100013) Add: 11/F, Tower B, Global Trade Center, No.36 North Third Ring Road East, Dongcheng District, Beijing, 100013, PRC Tel: 010-52213236/7 www.junzhilawyer.com 1 / 6 法律意见书 北京市君致律师事务所 关于江苏东华测试技术股份有限公司 2024年年度股东会之法律意见书 致：江苏东华测试技术股份有限公司 江苏东华测试技术股份有限公司（以下简称"公司"）2024年年度股东会（以下简 称"本次股东会"）于2025年5月9日（星期五）下午14：00在公司一楼会议室召开，北 京市君致 ...

Core Viewpoint - The aviation engine concept sector has shown a positive performance, with a 2.86% increase, ranking 7th among various concept sectors, indicating strong investor interest and potential growth in this area [1][2]. Market Performance - As of May 8, the aviation engine concept saw 74 stocks rise, with notable gainers including Chenxi Aviation and Huarun Co., both reaching a 20% limit up. Other significant performers included Aileda, Rifa Precision Machinery, and Xiling Power, which rose by 9.76%, 7.75%, and 7.37% respectively [1]. - Conversely, stocks such as Maixinlin, Julun Intelligent, and Jizhi Co. experienced declines of 2.64%, 2.55%, and 1.27% respectively [1]. Capital Flow - The aviation engine concept sector experienced a net outflow of 678 million yuan from major funds, with 38 stocks receiving net inflows. Seven stocks saw net inflows exceeding 30 million yuan, led by Haoneng Co. with a net inflow of 136 million yuan [2][3]. - Other notable net inflows included Hangfa Power, Rifa Precision Machinery, and AVIC Heavy Machinery, with net inflows of 81.44 million yuan, 62.90 million yuan, and 56.73 million yuan respectively [2]. Fund Inflow Ratios - Haoneng Co. led the fund inflow ratio with 48.12%, followed by New Dazhou A and Antai Technology at 11.99% and 10.86% respectively [3].

Stock Recommendations - Donghua Testing (300354.SZ) shows strong order fulfillment and is expected to benefit from its advanced sensor capabilities, with an EPS forecast of 1.22 in 2025, up from 0.88 in 2024[3] - Daotong Technology (688208.SH) reported a 26.71% revenue growth in Q1 2025 and a 57.50% increase in net profit, maintaining a high growth trajectory[3] - Shuanghuan Transmission (002472.SZ) is expected to see continued growth in its core business driven by new energy and smart execution mechanisms, with an EPS forecast of 1.59 in 2025[3] Financial Performance Highlights - Xinyiseng (300502.SZ) achieved a revenue of 86.47 billion yuan in 2024, a 179.15% increase year-on-year, and a net profit of 28.38 billion yuan, up 312.26%[4] - Kexing Pharmaceutical (688136.SH) expanded its overseas sales network, with a projected EPS of 0.51 in 2025, significantly up from 0.16 in 2024[3] - Kaiying Network (002517.SZ) reported a revenue of 51.18 billion yuan in 2024, a 19.16% increase, and a net profit of 16.28 billion yuan, up 11.41%[5] Market Trends and Valuation - The market performance of the recommended stocks shows that Kexing Pharmaceutical had the highest increase of over 50% in the last month, while Xinyiseng and Donghua Testing had turnover rates exceeding 100%[20] - The average PE ratio for the recommended stocks is below 50, with Kexing Pharmaceutical having the highest at 170.61, indicating a potential for growth despite high valuation[20] - The largest market capitalization among the recommended stocks is for Juzhi Biological (2367.HK) at 795.15 billion yuan, followed by Xinyiseng at 636.44 billion yuan[20]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [5]. Core Insights - The company achieved a revenue of 502.2 million yuan in 2024, representing a year-on-year growth of 32.79%. The net profit attributable to shareholders was 121.88 million yuan, up 38.90% year-on-year [1]. - In Q1 2025, the company reported a revenue of 109 million yuan, a slight increase of 4.25% year-on-year, with net profits of 29 million yuan, reflecting a year-on-year growth of 5.64% [1]. - The company benefits from strong market demand, supportive national policies, enhanced R&D capabilities, and stable customer relationships, contributing to steady revenue growth [2]. Financial Performance - The gross margin for 2024 was 66.37%, an increase of 0.90 percentage points year-on-year, while the net profit margin was 24.27%, up 1.07 percentage points [3]. - The company’s R&D expense ratio was 12.22% in 2024, indicating a commitment to maintaining its core competitiveness through continuous investment in research and development [3]. Business Development - The company has developed a complete product line for its custom measurement and control systems, and has introduced high-performance sensors that break the monopoly of imported technologies [4]. - The six-dimensional force sensor is currently in small-batch trial production, with potential benefits expected from the growth of humanoid robots [4]. Profit Forecast - The company is projected to achieve revenues of 666.78 million yuan, 857.94 million yuan, and 1.08764 billion yuan for the years 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is expected to be 169.12 million yuan, 224.72 million yuan, and 293.97 million yuan for the same years [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a total operating revenue of 502 million yuan in 2024, representing a year-on-year growth of 32.79%, and a net profit attributable to shareholders of 122 million yuan, up 38.90% year-on-year [4][5] - The company's core business competitiveness continues to strengthen, with the structural mechanics performance testing system generating revenue of 301 million yuan in 2024, accounting for 60.01% of total revenue, and growing by 35.79% year-on-year [5] - The company is focusing on high-reliability sensor products and has made advancements in the robotics field, with the development of a six-component torque sensor for various applications [6] Financial Performance Summary - In 2024, the company achieved a gross profit margin of 66.37%, which increased by 0.90 percentage points compared to 2023, and a net profit margin of 24.10%, also up by 0.90 percentage points [5] - For Q1 2025, the company reported a revenue of 109 million yuan, a growth of 4.25%, and a net profit of 29 million yuan, up 5.64% [4] - The company forecasts revenues of 658 million yuan, 855 million yuan, and 1.11 billion yuan for 2025, 2026, and 2027 respectively, with net profits of 170 million yuan, 228 million yuan, and 302 million yuan for the same years [7][10] Valuation Metrics - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.23 yuan, 1.65 yuan, and 2.18 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 32, 24, and 18 [7][10] - The company maintains a strong return on equity (ROE) forecast, expected to reach 19.2% in 2025 and 23.0% in 2027 [10][14]

Group 1: Financial Performance - In 2024, the company achieved total operating revenue of 502 million, a year-on-year increase of 32.79% [1] - The net profit attributable to shareholders reached 122 million, up 38.90% year-on-year, while the net profit after deducting non-recurring items was 120 million, reflecting a growth of 41.50% [1] - The weighted average return on equity was 17.21% [1] - In Q1 2025, the company reported revenue of 109 million, an increase of 4.25%, and a net profit of 29 million, up 5.64% [1] Group 2: Business Segments - The structural mechanics performance testing system generated revenue of 301 million in 2024, accounting for 60.01% of total revenue, with a year-on-year growth of 35.79% [1] - The electrochemical workstation, the second largest business segment, achieved revenue of 88 million, representing 17.62% of total revenue, and a year-on-year increase of 52.26% [1] - The company's gross profit margin for 2024 was 66.37%, an increase of 0.90 percentage points from 2023, while the net profit margin was 24.10%, also up by 0.90 percentage points [1] - In Q1 2025, the gross profit margin and net profit margin continued to grow, reaching 68.66% and 26.27% respectively [1] Group 3: Research and Development - The company has a strong focus on independent research and development, continuously innovating various sensors suitable for different environments [2] - In 2024, the company developed a six-component torque sensor applicable in robotics, scientific research, and automated testing, with small-scale trial production and partial market promotion already underway [2] - The Donghua Calibration Laboratory became one of the first CNAS laboratories in China capable of testing multi-dimensional force/torque sensors for robotics [2] Group 4: Investment Outlook - The company is expected to achieve revenues of 658 million, 855 million, and 1.111 billion in 2025, 2026, and 2027 respectively, with net profits of 170 million, 228 million, and 302 million for the same years [3] - The earnings per share (EPS) are projected to be 1.23, 1.65, and 2.18 for 2025, 2026, and 2027 respectively [3] - The current price-to-earnings (PE) ratios are estimated to be 32, 24, and 18 for the years 2025, 2026, and 2027 [3]